Price T Rowe Associates Inc. MD Has $93.27 Million Stake in Humana Inc. $HUM

Key Points

• Price T Rowe Associates Inc. MD significantly reduced its stake in Humana Inc. by 83.6%, ending the quarter with a worth of $93.27 million and holding 352,503 shares.
• Analysts have mixed views on Humana, with several institutions lowering their price targets, leading to a consensus rating of "Hold" and an average price target of $283.29.
• Humana recently declared a quarterly dividend of $0.885 per share, with a dividend yield of 1.2% and a payout ratio of 27.17%.

Price T Rowe Associates Inc. MD decreased its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 83.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 352,503 shares of the insurance provider's stock after selling 1,801,837 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.29% of Humana worth $93,273,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after purchasing an additional 46 shares during the last quarter. Riverview Trust Co bought a new stake in shares of Humana during the first quarter worth about $34,000. Garde Capital Inc. bought a new stake in shares of Humana during the first quarter worth about $36,000. Zions Bancorporation National Association UT bought a new stake in shares of Humana during the first quarter worth about $37,000. Finally, Whipplewood Advisors LLC grew its holdings in shares of Humana by 639.1% during the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after purchasing an additional 147 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on HUM. Bank of America reduced their price target on Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a report on Tuesday, June 17th. Wall Street Zen cut Humana from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Morgan Stanley reduced their target price on Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a report on Thursday, July 31st. Royal Bank Of Canada upped their target price on Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a report on Thursday, August 21st. Finally, Robert W. Baird reduced their target price on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Seven investment analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $283.29.

Humana Stock Performance

Shares of HUM stock opened at $297.78 on Tuesday. The stock has a market capitalization of $35.81 billion, a PE ratio of 22.85, a PEG ratio of 1.76 and a beta of 0.44. Humana Inc. has a one year low of $206.87 and a one year high of $382.72. The business's 50 day simple moving average is $249.83 and its 200 day simple moving average is $253.46. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.Humana's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio is presently 27.17%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.